Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy · Delayed Price · Currency is EUR 51.50
+0.40 (0.78%)
Oct 22, 2025, 5:37 PM CET
BIT:REC Revenue
Recordati Industria Chimica e Farmaceutica had revenue of 643.88M EUR in the quarter ending June 30, 2025, with 11.43% growth. This brings the company's revenue in the last twelve months to 2.48B, up 11.51% year-over-year. In the year 2024, Recordati Industria Chimica e Farmaceutica had annual revenue of 2.34B with 12.45% growth.
Revenue (ttm)
2.48B
Revenue Growth
+11.51%
P/S Ratio
4.28
Revenue / Employee
546.32K
Employees
4,583
Market Cap
10.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.34B | 259.23M | 12.45% |
| Dec 31, 2023 | 2.08B | 229.02M | 12.36% |
| Dec 31, 2022 | 1.85B | 273.23M | 17.29% |
| Dec 31, 2021 | 1.58B | 131.21M | 9.06% |
| Dec 31, 2020 | 1.45B | -32.98M | -2.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Amplifon | 2.41B |
| DiaSorin | 1.22B |
| Safilo Group | 998.89M |
| EL.En. | 579.71M |
| GPI S.p.A. | 531.42M |
| Garofalo Health Care | 474.78M |
| Svas Biosana | 134.95M |
| Talea Group | 132.17M |
Recordati Industria Chimica e Farmaceutica News
- 3 months ago - Amarin targets $70M cost savings and accelerates VAZKEPA European expansion through Recordati partnership - Seeking Alpha
- 3 months ago - Italy's Recordati CEO sees rare disease drugs exempt from U.S. tariffs - Reuters
- 3 months ago - Five years after COVID, pharma shares languish in US policy limbo - Reuters
- 4 months ago - Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA - Benzinga
- 4 months ago - Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges - Benzinga
- 4 months ago - Amarin inks licensing deal with Recordati for lead drug Vazkepa - Seeking Alpha
- 5 months ago - Recordati reports Q1 results - Seeking Alpha
- 5 months ago - RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2% - GlobeNewsWire